APO Research
Talk to an analyst

APO RESEARCH · REPORT

Fusion Protein Anti-VEGF Ophthalmic Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Outlook and Growth Opportunities 2026

27 December 2025193 pages

Choose your research edition.

Industry ResearchFusion Protein Anti-VEGF Ophthalmic Drugs Industry Research Report 2026107 pages · $2,950 USDIndustry Growth & TrendsGlobal Fusion Protein Anti-VEGF Ophthalmic Drugs Industry Growth and Trends Forecast to 203279 pages · $3,450 USDMarket StructureGlobal Fusion Protein Anti-VEGF Ophthalmic Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032177 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Fusion Protein Anti-VEGF Ophthalmic Drugs Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Fusion Protein Anti-VEGF Ophthalmic Drugs Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Fusion Protein Anti-VEGF Ophthalmic Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Fusion Protein Anti-VEGF Ophthalmic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Fusion Protein Anti-VEGF Ophthalmic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Fusion Protein Anti-VEGF Ophthalmic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Fusion Protein Anti-VEGF Ophthalmic Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Fusion Protein Anti-VEGF Ophthalmic Drugs market include Biocon Biologics, Regeneron Pharmaceuticals, Chengdu Kanghong Pharmaceutical and Samsung Bioepis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Fusion Protein Anti-VEGF Ophthalmic Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Fusion Protein Anti-VEGF Ophthalmic Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Fusion Protein Anti-VEGF Ophthalmic Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Fusion Protein Anti-VEGF Ophthalmic Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Fusion Protein Anti-VEGF Ophthalmic Drugs Segment by Company

Biocon Biologics

Regeneron Pharmaceuticals

Chengdu Kanghong Pharmaceutical

Samsung Bioepis

Fusion Protein Anti-VEGF Ophthalmic Drugs Segment by Type

Conbercept

Aflibercept

Fusion Protein Anti-VEGF Ophthalmic Drugs Segment by Application

Retail Pharmacies

Hospital and Clinic

Other

Fusion Protein Anti-VEGF Ophthalmic Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Fusion Protein Anti-VEGF Ophthalmic Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Fusion Protein Anti-VEGF Ophthalmic Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Fusion Protein Anti-VEGF Ophthalmic Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Fusion Protein Anti-VEGF Ophthalmic Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Fusion Protein Anti-VEGF Ophthalmic Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Fusion Protein Anti-VEGF Ophthalmic Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Fusion Protein Anti-VEGF Ophthalmic Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Fusion Protein Anti-VEGF Ophthalmic Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Fusion Protein Anti-VEGF Ophthalmic Drugs industry.

Chapter 3: Detailed analysis of Fusion Protein Anti-VEGF Ophthalmic Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Fusion Protein Anti-VEGF Ophthalmic Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Fusion Protein Anti-VEGF Ophthalmic Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Fusion Protein Anti-VEGF Ophthalmic Drugs Industry Trends Table 2. Fusion Protein Anti-VEGF Ophthalmic Drugs Industry Drivers Table 3. Fusion Protein Anti-VEGF Ophthalmic Drugs Industry Opportunities and Challenges Table 4. Fusion Protein Anti-VEGF Ophthalmic Drugs Industry Restraints Table 5. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Share by Company (2021-2026) Table 7. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Company, Product Type & Application Table 13. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Fusion Protein Anti-VEGF Ophthalmic Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Conbercept Table 18. Significant Companies of Aflibercept Table 19. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Volume Share by Type (2021-2026) Table 23. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Volume Share by Type (2027-2032) Table 24. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type (2021-2026) Table 28. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Retail Pharmacies Table 30. Significant Companies of Hospital and Clinic Table 31. Significant Companies of Other Table 32. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Volume Share by Application (2021-2026) Table 36. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Volume Share by Application (2027-2032) Table 37. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application (2021-2026) Table 41. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application (2027-2032) Table 42. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Region (2021-2026) & (K Units) Table 44. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Region (2021-2026) Table 45. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Region (2027-2032) & (K Units) Table 46. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Region (2027-2032) Table 47. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Region (2021-2026) Table 50. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Region (2027-2032) Table 52. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Country (2021-2026) & (K Units) Table 57. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2021-2026) Table 58. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Country (2027-2032) & (K Units) Table 59. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2027-2032) Table 60. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Market Share by Country (2021-2026) Table 62. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Market Share by Country (2027-2032) Table 64. Biocon Biologics Company Information Table 65. Biocon Biologics Business Overview Table 66. Biocon Biologics Fusion Protein Anti-VEGF Ophthalmic Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Biocon Biologics Fusion Protein Anti-VEGF Ophthalmic Drugs Product Portfolio Table 68. Biocon Biologics Recent Development Table 69. Regeneron Pharmaceuticals Company Information Table 70. Regeneron Pharmaceuticals Business Overview Table 71. Regeneron Pharmaceuticals Fusion Protein Anti-VEGF Ophthalmic Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Regeneron Pharmaceuticals Fusion Protein Anti-VEGF Ophthalmic Drugs Product Portfolio Table 73. Regeneron Pharmaceuticals Recent Development Table 74. Chengdu Kanghong Pharmaceutical Company Information Table 75. Chengdu Kanghong Pharmaceutical Business Overview Table 76. Chengdu Kanghong Pharmaceutical Fusion Protein Anti-VEGF Ophthalmic Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Chengdu Kanghong Pharmaceutical Fusion Protein Anti-VEGF Ophthalmic Drugs Product Portfolio Table 78. Chengdu Kanghong Pharmaceutical Recent Development Table 79. Samsung Bioepis Company Information Table 80. Samsung Bioepis Business Overview Table 81. Samsung Bioepis Fusion Protein Anti-VEGF Ophthalmic Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Samsung Bioepis Fusion Protein Anti-VEGF Ophthalmic Drugs Product Portfolio Table 83. Samsung Bioepis Recent Development Table 84. Key Raw Materials Table 85. Raw Materials Key Suppliers Table 86. Fusion Protein Anti-VEGF Ophthalmic Drugs Distributors List Table 87. Fusion Protein Anti-VEGF Ophthalmic Drugs Customers List Table 88. Research Programs/Design for This Report Table 89. Authors List of This Report Table 90. Secondary Sources Table 91. Primary Sources List of Figures Figure 1. Fusion Protein Anti-VEGF Ophthalmic Drugs Product Image Figure 2. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales (2021-2032) & (K Units) Figure 5. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Conbercept Image Figure 10. Aflibercept Image Figure 11. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Volume Share by Type (2021-2032) Figure 14. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type (2021-2032) Figure 17. Retail Pharmacies Image Figure 18. Hospital and Clinic Image Figure 19. Other Image Figure 20. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Volume Share by Application (2021-2032) Figure 23. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application (2021-2032) Figure 26. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. North America Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. South America Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Fusion Protein Anti-VEGF Ophthalmic Drugs Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Conbercept
  • Aflibercept
Applications
  • Retail Pharmacies
  • Hospital and Clinic
  • Other
Companies covered
  • Biocon Biologics
  • Regeneron Pharmaceuticals
  • Chengdu Kanghong Pharmaceutical
  • Samsung Bioepis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Fusion Protein Anti-VEGF Ophthalmic Drugs Market Dynamics
  1. 2.1 Fusion Protein Anti-VEGF Ophthalmic Drugs Industry Trends
  2. 2.2 Fusion Protein Anti-VEGF Ophthalmic Drugs Industry Drivers
  3. 2.3 Fusion Protein Anti-VEGF Ophthalmic Drugs Industry Opportunities and Challenges
  4. 2.4 Fusion Protein Anti-VEGF Ophthalmic Drugs Industry Restraints
3 Fusion Protein Anti-VEGF Ophthalmic Drugs Market by Company
  1. 3.1 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Company Ranking (2024-2026)
  6. 3.6 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Company Product Type and Application
  8. 3.8 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Fusion Protein Anti-VEGF Ophthalmic Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Fusion Protein Anti-VEGF Ophthalmic Drugs Market by Type
  1. 4.1 Fusion Protein Anti-VEGF Ophthalmic Drugs Type Introduction
  2. 4.1.1 Conbercept
  3. 4.1.2 Aflibercept
  4. 4.2 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Volume by Type
  5. 4.2.1 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value by Type
  9. 4.3.1 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value by Type (2021-2032)
  11. 4.3.3 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type (2021-2032)
5 Fusion Protein Anti-VEGF Ophthalmic Drugs Market by Application
  1. 5.1 Fusion Protein Anti-VEGF Ophthalmic Drugs Application Introduction
  2. 5.1.1 Retail Pharmacies
  3. 5.1.2 Hospital and Clinic
  4. 5.1.3 Other
  5. 5.2 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Volume by Application
  6. 5.2.1 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value by Application
  10. 5.3.1 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application (2021-2032)
6 Fusion Protein Anti-VEGF Ophthalmic Drugs Regional Sales and Value Analysis
  1. 6.1 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Region (2027-2032)
  5. 6.3 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Country, 2025 VS 2032
7 Fusion Protein Anti-VEGF Ophthalmic Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Country (2027-2032)
  6. 7.4 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Biocon Biologics
  2. 8.1.1 Biocon Biologics Company Information
  3. 8.1.2 Biocon Biologics Business Overview
  4. 8.1.3 Biocon Biologics Fusion Protein Anti-VEGF Ophthalmic Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Biocon Biologics Fusion Protein Anti-VEGF Ophthalmic Drugs Product Portfolio
  6. 8.1.5 Biocon Biologics Recent Developments
  7. 8.2 Regeneron Pharmaceuticals
  8. 8.2.1 Regeneron Pharmaceuticals Company Information
  9. 8.2.2 Regeneron Pharmaceuticals Business Overview
  10. 8.2.3 Regeneron Pharmaceuticals Fusion Protein Anti-VEGF Ophthalmic Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Regeneron Pharmaceuticals Fusion Protein Anti-VEGF Ophthalmic Drugs Product Portfolio
  12. 8.2.5 Regeneron Pharmaceuticals Recent Developments
  13. 8.3 Chengdu Kanghong Pharmaceutical
  14. 8.3.1 Chengdu Kanghong Pharmaceutical Company Information
  15. 8.3.2 Chengdu Kanghong Pharmaceutical Business Overview
  16. 8.3.3 Chengdu Kanghong Pharmaceutical Fusion Protein Anti-VEGF Ophthalmic Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Chengdu Kanghong Pharmaceutical Fusion Protein Anti-VEGF Ophthalmic Drugs Product Portfolio
  18. 8.3.5 Chengdu Kanghong Pharmaceutical Recent Developments
  19. 8.4 Samsung Bioepis
  20. 8.4.1 Samsung Bioepis Company Information
  21. 8.4.2 Samsung Bioepis Business Overview
  22. 8.4.3 Samsung Bioepis Fusion Protein Anti-VEGF Ophthalmic Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Samsung Bioepis Fusion Protein Anti-VEGF Ophthalmic Drugs Product Portfolio
  24. 8.4.5 Samsung Bioepis Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Fusion Protein Anti-VEGF Ophthalmic Drugs Value Chain Analysis
  2. 9.1.1 Fusion Protein Anti-VEGF Ophthalmic Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Mode & Process
  6. 9.2 Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Fusion Protein Anti-VEGF Ophthalmic Drugs Distributors
  9. 9.2.3 Fusion Protein Anti-VEGF Ophthalmic Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst